Abstract
Cancer cells create a microenvironment that prevents tumor rejection by the host’s immune system. The activation of pattern recognition receptors (PRRs) can elicit an innate immune response and guide the adaptive immune response to overcome this. dsRNA analogs can trigger TLR3, RIG-I, MDA5, NLRP3 and several other PRRs to induce not only robust immune response against cancer but also programmed cell death. This review focuses on the signal pathways activated by dsRNA and examines examples of their clinical application in cancer treatment.
Keywords: Adjuvant, cancer vaccine, cross-presentation, cytokine, cytotoxic T lymphocyte, dendritic cell, double-stranded RNA, inflammasome, immune response, immunoediting, immunotherapy, melanoma differentiation-associated gene 5, nucleotide-binding domain and leucine-rich repeat containing gene family pyrin domain 3, polyadenylic-polyuridylic acid, polyinosinic-polycytidylic acid, poly (I:C12U), poly (ICLC), retinoic acid-inducible gene-I, T helper cell, toll-like receptor, tumor, tumor associated antigen.
Anti-Cancer Agents in Medicinal Chemistry
Title:Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends
Volume: 14 Issue: 2
Author(s): Bo Jin, Liu-Fang Cheng, Kai Wu, Xiao-Hong Yu and Anthony E.T. Yeo
Affiliation:
Keywords: Adjuvant, cancer vaccine, cross-presentation, cytokine, cytotoxic T lymphocyte, dendritic cell, double-stranded RNA, inflammasome, immune response, immunoediting, immunotherapy, melanoma differentiation-associated gene 5, nucleotide-binding domain and leucine-rich repeat containing gene family pyrin domain 3, polyadenylic-polyuridylic acid, polyinosinic-polycytidylic acid, poly (I:C12U), poly (ICLC), retinoic acid-inducible gene-I, T helper cell, toll-like receptor, tumor, tumor associated antigen.
Abstract: Cancer cells create a microenvironment that prevents tumor rejection by the host’s immune system. The activation of pattern recognition receptors (PRRs) can elicit an innate immune response and guide the adaptive immune response to overcome this. dsRNA analogs can trigger TLR3, RIG-I, MDA5, NLRP3 and several other PRRs to induce not only robust immune response against cancer but also programmed cell death. This review focuses on the signal pathways activated by dsRNA and examines examples of their clinical application in cancer treatment.
Export Options
About this article
Cite this article as:
Jin Bo, Cheng Liu-Fang, Wu Kai, Yu Xiao-Hong and Yeo E.T. Anthony, Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (2) . https://dx.doi.org/10.2174/18715206113136660373
DOI https://dx.doi.org/10.2174/18715206113136660373 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transplacental Antioxidants Inhibit Lung Tumors in Mice Exposed to Cigarette Smoke After Birth: A Novel Preventative Strategy?
Current Cancer Drug Targets The ARRONAX Project
Current Radiopharmaceuticals S16020 Pyridocarbazole Derivatives Display High Activity to Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Development of Amino Acid-Based Radiopharmaceuticals for Tumor Imaging
Mini-Reviews in Medicinal Chemistry Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism Proteomics in the Search for Biomarkers of Animal Cancer
Current Protein & Peptide Science Recent Advances in Pharmacological Interventions of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome
Current Pharmaceutical Design 18F-Labeled Proteins
Current Pharmaceutical Biotechnology Will Medicinal Cannabinoids Prove to be Useful Clinically?
Current Drug Therapy Tandem Multicomponent Reactions Toward the Design and Synthesis of Novel Antibacterial and Cytotoxic Motifs
Current Medicinal Chemistry Impact of Renin-Angiotensin System in Hepatocellular Carcinoma
Current Cancer Drug Targets The Impact of L-Carnitine and Coenzyme Q10 as Protection Against Busulfan-Oxidative Stress in the Liver of Adult Rats
The Natural Products Journal The Role of Capecitabine in the Management of Tumors of the Digestive System
Reviews on Recent Clinical Trials Targeted Drug Delivery System for Platinum-based Anticancer Drugs
Mini-Reviews in Medicinal Chemistry High Performance Liquid Chromatographic Approaches to Mass Spectrometry Based Metabolomics
Current Metabolomics Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Current Topics in Medicinal Chemistry Pharmacokinetic Profiles of Anticancer Herbal Medicines in Humans and the Clinical Implications
Current Medicinal Chemistry The Mechanisms of Anticancer Agents by Genistein and Synthetic Derivatives of Isoflavone
Mini-Reviews in Medicinal Chemistry Expression of mTOR/70S6K Signaling Pathway in Melanoma Cancer Cells and the Effects of Dacarbazine and Metformin
Current Cancer Therapy Reviews